1-6 of 6
Melih Acar
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Magrolimab, Rituximab and Acalabrutinib for Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Phase 1 PRISM Trial

Sven de Vos, Patrick M. Reagan, Manish R. Patel, Nakhle S. Saba, Andrew Mortlock, Virginie Cerec, Veerendra Munugalavadla, Melih Acar, Barrett Nuttall, David Jenkins, Rafael White, Megan Callahan, Alessandra Forcina, Mark Roschewski, Ian W. Flinn
Journal: Blood
Blood (2022) 140 (Supplement 1): 6635–6637.
https://doi.org/10.1182/blood-2022-162447
Published: 2022
Journal Articles

Longitudinal Mutation Profiling in CLL Patients during Acalabrutinib Therapy and at Progression

Clare Sun, Melih Acar, David Jenkins, Barrett Nuttall, Rafael White, Veerendra Munugalavadla, Adrian Wiestner
Journal: Blood
Blood (2022) 140 (Supplement 1): 9847–9848.
https://doi.org/10.1182/blood-2022-159525
Published: 2022
Journal Articles

A Phase 1 Study of the Combination of Acalabrutinib and AZD9150 in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Mark Roschewski, Veerendra Munugalavadla, Barrett Nuttall, Kathleen Burke, Melih Acar, Rafael White, Maria Udriste, Shringi Sharma, Brian Dougherty, Ian Flinn, Nakhle S. Saba, Patrick M. Reagan, Sven de Vos, Hendrik-Tobias Arkenau, Graham P. Collins, Andrew Mortlock, Manish R. Patel
Journal: Blood
Blood (2021) 138 (Supplement 1): 1418.
https://doi.org/10.1182/blood-2021-147567
Published: 2021
Journal Articles

Effect of Luspatercept on Biomarkers of Erythropoiesis in Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the Medalist Trial

Uwe Platzbecker, Yiming Zhu, Xianwei Ha, Alberto Risueño, Esther Chan, George Zhang, Diana R. Dunshee, Melih Acar, Jeevan K. Shetty, Rodrigo Ito, Kyle MacBeth, Valeria Santini, Maciej W. Garbowski, Pierre Fenaux, MD PhD, Martin Schwickart
Journal: Blood
Blood (2020) 136 (Supplement 1): 38–39.
https://doi.org/10.1182/blood-2020-136705
Published: 2020
Journal Articles

Rapamycin (Sirolimus) and Rap-536 Increase Red Blood Cell Parameters through Distinct Mechanisms in Wild-Type and Thalassemic Mice

Melih Acar, Madhulika Jupelli, Kyle MacBeth, Martin Schwickart
Journal: Blood
Blood (2020) 136 (Supplement 1): 17.
https://doi.org/10.1182/blood-2020-137392
Published: 2020
Journal Articles

Rap-536 Induces Reticulocyte Maturation in Wild-Type Mice, Increases Survival of Beta-Thalassemic Reticulocytes, and Increases Red Blood Cells in a Mouse Model of Alpha-Thalassemia

Melih Acar, Madhulika Jupelli, Roberto A. Abbiati, Harish N. Ramanathan, Cristina C. Santini, Alexander Ratushny, Diana R. Dunshee, Daniel Lopes de Menezes, PhD, Kyle MacBeth, Rajasekhar N.V.S. Suragani, Remco Loos, Martin Schwickart
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–19.
https://doi.org/10.1182/blood-2020-137373
Published: 2020